7 news items
METIS Phase 3 Clinical Trial Met Primary Endpoint Significantly Delaying Time to Intracranial Progression with Improved Quality of Life Deterioration-Free Survival
NVCR
3 Jun 24
. The Private Securities Litigation Reform Act of 1995 permits this discussion
Novocure Secures New $400 Million Multi-Tranche Non-Dilutive Debt Financing from Pharmakon
NVCR
2 May 24
only as of the date hereof. The Private Securities Litigation Reform Act of 1995 permits this discussion
Novocure Reports First Quarter 2024 Financial Results
NVCR
2 May 24
statement, except as required by law. Any forward-looking statements herein speak only as of the date hereof. The Private Securities Litigation Reform
Results of Novocure's METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024
NVCR
24 Apr 24
statement, except as required by law. Any forward-looking statements herein speak only as of the date hereof. The Private Securities Litigation Reform
Novocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research (AACR) Annual Meeting 2024
NVCR
5 Apr 24
Securities Litigation Reform Act of 1995 permits this discussion
1kc9gvd2
NVCR
ZLAB
27 Mar 24
-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements
qip7s2y00
NVCR
27 Mar 24
. Any forward-looking statements herein speak only as of the date hereof. The Private Securities Litigation Reform Act of 1995 permits this discussion
- Prev
- 1
- Next